We are international
• treatment options TEXT SIZE   
Novel Therapies

Novel therapies include treatments that has been shown to be effective for myeloma and those that have active clinical trials.
EMPLICITI® (elotuzumab)
EMPLICITI (elotuzumab) is a prescription medicine used to treat multiple myeloma in combination with the medicines REVLIMID® (lenalidomide) and dexamethasone in people who have received one to three prior treatments for their multiple myeloma. It is not known if EMPLICITI is safe and effective in children.
NINLARO® (ixazomib)
NINLARO® (ixazomib) belongs to the same class of drugs as Velcade® (bortezomib), called proteasome inhibitors, and it is being developed by Millennium Pharmaceuticals, the same company that developed Velcade.

DARZALEX® (daratumumab)
DARZALEX™ is a human CD38-directed monoclonal antibody indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent.
POMALYST® (pomalidomide) capsules
Pomalyst® is the newest oral immun­omodulatory drug (IMiD®). Approved by the FDA in 2013, Pomalyst is chemically related to thalidomide and lenalidomide, which was approved by the FDA in 2006, but Pomalyst has been enhanced to be more effective.

KYPROLIS® (carfilzomib)
Kyprolis, a next-generation proteasome inhibitor, received expanded FDA approval in January, 2016. It is now approved in combination with dexamethasone, or with Revlimid(R) (lenalidomide) + dexamethasone, for the treatment of patients with relapsed or refractory myeloma who have received 1 to 3 prior lines of therapy. It is also approved as a single agent for the treatment of relapsed or refractory myeloma patients who have had 1 or more lines of therapy.
REVLIMID® (lenalidomide)
REVLIMID®, a potent immunomodulatory derivative (IMiD) of thalidomide, induces apoptosis in resistant MM cell lines and patient cells and, more importantly, decreases binding of MM cells to bone marrow stromal cells.

THALOMID® (Thalidomide)
Helpful information about Thalidomide Therapy for patients and caregivers, including clinical trials with THALOMID®. Watch "Ask the Expert" videos from ASCO 2004 and the Lymphoma Myeloma Conference 2004.
VELCADE® (bortezomib) for Injection
VELCADE® is an antineoplastic agent available for intravenous injection (IV) use only. It has been approved by the FDA for the treatment of myeloma. Watch the "Ask the Expert" Videos from ASCO 2004 and Lymphoma Myeloma Conference 2004 on VELCADE® as treatment and in research.

Dexamethasone, an adrenal corticosteroid, is used to treat multiple myeloma.
DOXIL® is made of fat bubbles called liposomes that contain doxorubicin, a drug that has been used to treat cancer for over 20 years. In DOXIL, these liposomes are surrounded by a layer of hairlike strands made from polyethylene glycol.

Radiation Therapy
Radiation is often used for treatment of myeloma bone disease.